3rd Quarter Results

Summary by AI BETAClose X

Oxford Technology 2 VCT Plc reported its third-quarter results ending 30 November 2025, with net asset value per share showing mixed performance across its share classes, ranging from a 0.4% decrease for OT1 to a 3.1% increase for OT4. The primary drivers of these changes were the valuations of AIM-quoted investments Scancell Holdings Plc and Arecor Therapeutics Plc, with Arecor seeing positive clinical and commercial developments despite a modest share price increase from 62p to 70p, while Scancell's share price declined from 9.8p to 9.3p despite promising trial results and potential platform spin-offs. Unquoted investments remained at their previous valuations, and no dividends were paid or portfolio companies bought or sold during the period.

Disclaimer*

UK 100

Latest directors dealings